Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: AI Image
The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.
Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.
Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.
Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know
The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.
Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).
The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.
The authors said the outbreaks highlighted measles' risks to maternal and newborn health.
Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.
The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.
Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.
The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.
As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.
The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.
The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.
"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.
Credit: AI Image
A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.
The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.
However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.
The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.
After 68 weeks:
Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.
The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.
"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.
What Are The Side Effects?
Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.
Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.
Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.
The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.
Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.
For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.
Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report
Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.
A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.
The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.
However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.
It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.
Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.
Credit: Health Ministry/X
Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.
Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.
The President noted that malaria remains a serious public health challenge in several countries, including India.
Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.
"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.
India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.
As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.
Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.
She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.
Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.
The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.
She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.
Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.
Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.
Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.
The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.
"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.
The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.
© $2026 Times Horizon Private Limited